A case of pituitary neuroendocrine carcinoma defying survival timeline
Endocrinology, Diabetes & Metabolism Case Reports · 01.10.2026 · 2026 (4)
DOI: 10.1530/edm-25-0160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 01.10.2026. Verfasst von Somdatta Giri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, JIPMER , Puducherry, India. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Summary Metastatic pituitary neuroendocrine tumours (PitNETs) are exceedingly rare, accounting for less than 0.2% of all pituitary tumours; they typically have a poor prognosis, with patient survival limited to 2–4 years because of aggressive local invasion and metastatic spread. We describe a unique case of a 50-year-old man with an adrenocorticotropic hormone (ACTH)-secreting pituitary macroadenoma initially resected in 2007 who subsequently developed multiple recurrences and ultimately developed a metastatic PitNET. The patient underwent repeated surgical resections, stereotactic radiosurgery, radiotherapy, and systemic therapies, including temozolomide (TMZ), peptide receptor radionuclide therapy (PRRT), and somatostatin analogues. Histopathology evolved from a low-grade to high-grade PitNET with a Ki-67 index of up to 50%, although p53 remained negative, possibly contributing to his unusually prolonged survival. Notably, methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter likely enhanced the patient’s favourable response to TMZ. Despite multiple intracranial and extracranial metastases, including involvement of the temporal lobe, parotid gland, and scapular bone, the patient survived for 17 years from the initial diagnosis and for 9 years from a confirmed metastatic disease, defying the typical prognosis. This case highlights the importance of vigilant long-term surveillance; the recognition of prognostic markers, such as Ki-67, p53, and MGMT status; and the role of multimodal therapy, including surgery, radiotherapy, and TMZ, in extending survival in patients with aggressive pituitary tumours. Although metastatic PitNETs generally portend a dismal outcome, individualised and sequential treatment strategies can occasionally result in exceptional long-term survival. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, JIPMER , Puducherry, India.
- Department of Diabetes and Endocrinology at Manipal Hospitals, Hebbal , Bangalore, India.
- Department of Neurosurgery, JIPMER , Puducherry, India.
- Department of Endocrinology at PGI , Chandigarh, India.
- Department of Radiation Oncology, JIPMER , Puducherry, India.
- Department of Pathology, JIPMER , Puducherry, India.
ORCID-Profile: Somdatta Giri, Pinaki Dutta, Jayaprakash Sahoo
Zitieren
APA
Giri, S., Rashmi, K. G., Gopalakrishnan, M. S., Kamalanathan, S. K., Dutta, P., Prem, S. S., Naik, D., Srinivas, B. H., Nagarajan, K., Halanaik, D., & Sahoo, J. (2026). A case of pituitary neuroendocrine carcinoma defying survival timeline. Endocrinology, Diabetes & Metabolism Case Reports, 2026(4). https://doi.org/10.1530/edm-25-0160
Vancouver
Giri S, Rashmi KG, Gopalakrishnan MS, Kamalanathan SK, Dutta P, Prem SS, et al. A case of pituitary neuroendocrine carcinoma defying survival timeline. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(4). doi:10.1530/edm-25-0160
BibTeX
@article{Giri2026,
author = {Giri, Somdatta and Rashmi, K G and Gopalakrishnan, M S and Kamalanathan, Sadish Kumar and Dutta, Pinaki and Prem, Shyama Sudha and Naik, Dukhabandhu and Srinivas, B H and Nagarajan, K and Halanaik, Dhanapathi and Sahoo, Jayaprakash},
title = {A case of pituitary neuroendocrine carcinoma defying survival timeline},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2026},
volume = {2026},
number = {4},
doi = {10.1530/edm-25-0160}
}
EUVIMED